ATPAF1: A Potential Drug Target and Biomarker for Mitochondrial Function

Target Name: ATPAF1

NCBI ID: G64756

ATPAF1

ATPAF1: A Potential Drug Target and Biomarker for Mitochondrial Function

ATP synthase (ATP synthase I) is a protein complex that plays a crucial role in generating ATP, the primary energy currency in the cell. The mitochondrial F1 complex assembly factor 1 (ATPAF1) is a protein that belongs to the F1 complex of ATP synthase. It is essential for the assembly and function of the ATP synthase I. The deregulation of ATPAF1 has been implicated in various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. As a result, targeting ATPAF1 has become an attractive research focus. In this article, we will discuss the structure and function of ATPAF1, its potential as a drug target, and its potential as a biomarker.

Structure and Function

ATPAF1 is a 21 kDa protein that contains 11 known protein subunits and 21 known protein interactions. ATPAF1 is composed of a nucleotide-binding domain (NBD), a Rossmann-fold, and a C-terminal T-loop. The NBD is the protein's binding site for ATP and is responsible for the formation of the ATP synthase I complex. The Rossmann-fold is a structural motif that is commonly found in proteins that interact with nucleotides, and it plays a critical role in ATPAF1's function. The C-terminal T-loop is a structural motif that is involved in the regulation of protein stability and functions.

ATPAF1 functions as a critical regulator of ATP synthase I. It plays a crucial role in the assembly and maintenance of the ATP synthase I complex. The NBD of ATPAF1 is responsible for the formation of the ATP synthase I complex, and the Rossmann-fold is involved in the interaction between the NBD and ATP. The C-terminal T-loop is involved in the regulation of ATP synthase I activity.

Potential Drug Target

The deregulation of ATPAF1 has been implicated in various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. The potential drug targets for ATPAF1 include inhibitors of the NBD, Rossmann-fold, and C-terminal T-loop. These inhibitors would target the various functions of ATPAF1, including the assembly and maintenance of the ATP synthase I complex, as well as its regulation of ATP production.

Potential Biomarker

ATPAF1 has also been identified as a potential biomarker for various diseases. The deregulation of ATPAF1 has been implicated in various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. The levels of ATPAF1 have been shown to be altered in these diseases, and the alterations in ATPAF1 levels may serve as a potential biomarker. The levels of ATPAF1 can be used as a biomarker to diagnose and monitor various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

Conclusion

In conclusion, ATPAF1 is a protein that plays a crucial role in the assembly and maintenance of the ATP synthase I complex. Its deregulation has been implicated in various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. As a result, targeting ATPAF1 has become an attractive research focus. The potential drug targets for ATPAF1 include inhibitors of the NBD, Rossmann-fold, and C-terminal T-loop. Additionally, ATPAF1 has also been identified as a potential biomarker for various diseases. Further research is needed to fully understand the role of ATPAF1 in disease progression and to develop effective treatments.

Protein Name: ATP Synthase Mitochondrial F1 Complex Assembly Factor 1

Functions: May play an essential role for the assembly of the mitochondrial F1-F0 complex

The "ATPAF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATPAF1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets